The R-Pharm Group has recently announced the commencement of clinical trials for the groundbreaking drug olokizumab, known as Artlegia, in its promising role to treat patients suffering from progressive pulmonary fibrosis. The experiment will be conducted in over 20 medical institutions in Moscow, St. Petersburg, Yaroslavl, Petrozavodsk, Kemerovo, Chelyabinsk, Izhevsk, and other cities.
The planned total number of participants is 116 patients. The study will evaluate the effectiveness and safety of olokizumab for the treatment of progressive fibrosing interstitial lung diseases.
“Progressive pulmonary fibrosis represents a significant medical and social problem, leading to disability and death in patients. Current treatment methods can slow down, but not stop, the progression of the disease. At the same time, in a number of patients, rapid progression is observed even despite the treatment,” said R-Pharm medical director Mikhail Samsonov.
